US private equity deal value fell 14.1 percent in the third quarter, according to PitchBook, and the industry has responded with the particular calm of people who would like you to think this was the plan. Meanwhile an Andreessen Horowitz-led round put 870 million dollars into a single company, which is roughly the opposite behaviour, performed in the same quarter, by people reading the same spreadsheets. Both things are true. That is the interesting part.
A fall in aggregate deal value gets reported as a slowdown, and in the narrow sense it is one. Less money moved. Fewer companies changed hands. Bankers who bill on completion had a thinner three months than bankers who bill on hours. But aggregate value is a blunt instrument, because it adds together two entirely different activities and calls them one market. There is the business of buying assets because the model says they will be worth more later, and there is the business of buying assets because capital must be deployed before the fund’s investment period closes. The second kind is what inflates a good quarter. Its absence is what deflates one.
Consider what a seasoned barista does when the beans are no longer at their peak. The amateur response is to pull more shots, faster, hoping that volume covers for a thinning flavour. The professional response is to pull fewer, dial the grind tighter, and accept that the queue will move slower because the alternative is serving something nobody comes back for. The machine is not broken in either case. What changes is the willingness to send out a cup you would not drink yourself. A 14.1 percent fall in deal value is a market that has stopped pulling shots to look busy.
The 870 million dollar exception matters for exactly that reason. When the general level of activity drops and individual cheques get larger, it is a sign that conviction is concentrating rather than evaporating. Firms are not sitting out. They are declining to spread the same capital across eleven adequate positions when one position looks genuinely mispriced. That is a different posture from fear, and it has a different consequence. Concentration raises the cost of being wrong while also raising the return on being right, which is the trade every allocator claims to want until the moment they have to sign for it.
For founders this reads as a harder room, and it is. The companies that got funded in a loose market were often funded by the margin – the last few million in a fund that needed to be somewhere by December. That marginal buyer has gone quiet. What remains is the buyer who has to justify the position to a committee that now has time to ask questions, because it is not processing a dozen other deals the same week. Attention is the scarce resource in a busy market and the abundant one in a slow market, and abundant attention is not a comfortable thing to be on the receiving end of.
The sector’s own economics also shift. Lower deal value with stable fund sizes means dry powder accumulates, and accumulated dry powder is a pressure system. It does not stay still indefinitely, because the fees that justify it are charged on committed capital rather than on cleverness. Somewhere in the next few quarters that pressure finds an outlet, and the deals written then will be judged against the ones not written now.
Fourteen percent less money moved, and the money that did move went further into fewer places. That is not a market losing its nerve. That is a market that finally tasted what it had been serving.
Source: Fortune, “US private equity deal value was down in Q3, PitchBook says”
